|Company Location||Milwaukee, WI|
|Company Address||10101 Innovation Drive, Suite 600|
Rejection is the major cause of transplant failure, and transplant recipients require lifelong rejection surveillance to guide modulation of immunosuppressant dosage and frequently require clinical interventions to improve organ function. Our initial test offering will be for cardiac transplant patients. The current gold standard surveillance test for these patients is the endomyocardial biopsy with histological interpretation by a pathologist, a procedure that is invasive, subject to sampling error, and expensive for both the patient and the healthcare system.
TAI Diagnostics has developed a proprietary noninvasive assay which utilizes patent-pending cf-DNA technology as a direct measurement of organ injury through quantitation of donor-specific cf-DNA released into the bloodstream from injured cells of a transplanted organ. The Quantitative Genotyping Assay requires only a small blood sample for processing in our CLIA certified and CAP accredited clinical reference laboratory. Scientific data to date indicates that the quantitative genotyping technique has a high degree of sensitivity and specificity, a rapid turnaround time, and can be offered at a very competitive price point.
Current job openings at TAI Diagnostics
- Biotech Manufacturing Specialist posted 11 days ago.